AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JUL 24 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Rearchers in Japan report that a vaccine containing cytokines encapsulated in biodegradable microparticles demonstrated a protective effect against liver cancer in a mouse model and in human clinical trials.
B.G. Peng and colleagues at the Institute of Physical and Chemical Research (RIKEN) in Japan evaluated vaccines to prevent recurrence of hepatocellular carcinoma. The investigators designed a vaccine containing cytokines encased within particles that degrade over time, providing a slow release of the cytokines rather than bolus release. Encapsulated cytokines included granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2).
In addition to the cytokines, the vaccine consisted of autologous hepatocellular carcinoma cells and tissues fragments and an adjuvant. Studies using a murine model indicated vaccine efficacy. When injected into syngeneic mice, the vaccine protected 33% of the mice against tumor formation after a hepatocellular carcinoma challenge (Autologous fixed tumor vaccine: A formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma, Japanese Journal of Cancer Research, 2002;93(4):363-368).
In phase I and IIa human clinical trials, the vaccine produced a delayed-type hypersensitivity (DTH) response against the tumor cell particles and fragments in 8 of 12 patients who had undergone curative resection ...
Source: HighBeam Research, Vaccine incorporating encapsulated cytokines protects against liver...